COVID-19 Vaccine: Newest Updates

CNBC.com, ” HEALTH AND SCIENCE
Johnson & Johnson reaches take care of U.S. for 100 million doses of coronavirus vaccine at greater than $1 billion.”

Milken Institute,  Quicker Cures Covid-19 Remedy and Vaccine Tracker.

U.S. Well being & Human Providers Reality Sheet: “Explaining Operation Warp Pace,” June 16, 2020.

Information launch, AstraZeneca, “COVID-19 vaccine AZD1222 confirmed sturdy immune responses in all members in Section I/II trial,” July 20, 2020 . 

The Lancet: “Security and immunogenicity of the ChAdOx1 nCoV-19 vaccine in opposition to SARS-CoV-2: a preliminary report of a section ½, single-blind, randomized managed trial.”

Information launch, Pfizer, “Pfizer and BioNTech Select Lead MRNA Vaccine Candidate,” “Pfizer and BioNTech announce settlement with U.S. authorities.”

Information launch, Moderna, “Moderna Proclaims Section 3 COVE Research of mRNA Vaccine In opposition to COVID-19 (mRNA-1273) Begins.”

Information launch, FDA, “Inovio’s Vaccine Candidate Reveals Promise in Early Trial.”

Information launch, Johnson & Johnson, “Johnson & Johnson Announce Acceleration of its COVID-19 Vaccine Candidate; Section 1-2a Scientific Trial to Start in Second Half of July.” 

Information launch, Merck: “How We’re Responding to the International Pandemic of COVID-19.”

Information launch, Novavax: “Novavax Introduced Constructive Section 1 Information for its COVID-19 Vaccine Candidate;” “Novavax Proclaims $1.6 Billion Funding From Operation Warp Pace.”

Information launch, GlaxoSmithKline: “Sanofi and GSK Chosen for Operation Warp Pace to Provide United States Authorities With 100 Million Doses of COVID-19 Vaccine.”  

MD Anderson Heart, “COVID-19 herd immunity: 7 questions, answered”

Nature: “Section 1 / 2 research of COVID-19 RNA vaccine BNT162b1 in adults.”

COVID-19 Prevention Community.

ClinicalTrials.gov

Information launch, Johnson & Johnson: “Johnson & Johnson Initiates Pivotal International Section 3 Scientific Trial of Janssen’s COVID-19 Vaccine Candidate.” 

 

Leave a Reply

Your email address will not be published. Required fields are marked *